Sundlof feels industry's NDI pain
This article was originally published in The Tan Sheet
Executive Summary
FDA's Center for Food Safety and Applied Nutrition currently rejects 80 percent of the new dietary ingredient notifications it receives "because industry doesn't really understand what we require," says center Director Stephen Sundlof. The NDI guidance is "still under review ... but we are pressing to get that out and we know that the industry really wants to have that guidance," Sundlof said at the Food and Drug Law Institute's annual conference April 22 in Washington. Supplement industry stakeholders have long said an NDI guidance would be a key incentive for developing new products, and Sundlof said he realizes publishing the guidance "would be really helpful" to industry. The recent switch by Sens. John McCain, R-Ariz., and Byron Dorgan, D-N.D., from sponsoring a bill that would put new burdens on the industry to backing legislation that requires FDA to complete the NDI notification guidance "as soon as possible" also could compel CFSAN's work (1"The Tan Sheet" March 15, 2010)
You may also be interested in...
Hatch Flips Focus To NDI Guidance In McCain Steroid Bill Negotiations
In a bit of legislative jiu-jitsu, congressional dietary supplement champions have redirected Sen. John McCain from sponsoring a bill that would put new burdens on industry to backing a provision that requires FDA publish a guidance stakeholders have been pushing for
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.